scholarly journals Corticosteroid-Binding Globulin Gene Mutations and Chronic Fatigue/Pain Syndromes: An Overview of Current Evidence

10.5772/29696 ◽  
2012 ◽  
Author(s):  
C. S. ◽  
D. J.
Keyword(s):  
Gene Mutations ◽  
Chronic Fatigue ◽  
Current Evidence ◽  
Pain Syndromes ◽  
Corticosteroid Binding Globulin ◽  
Globulin Gene

Association Between Chronic Fatigue Syndrome and the Corticosteroid‐Binding Globulin Gene ALA SER224Polymorphism

2004 ◽  
Vol 30 (3) ◽  
pp. 417-429 ◽  
Author(s):  
David J. Torpy ◽  
A. W. Bachmann ◽  
M. Gartside ◽  
J. E. Grice ◽  
J. M. Harris ◽  
...  
Keyword(s):  
Chronic Fatigue Syndrome ◽  
Chronic Fatigue ◽  
Fatigue Syndrome ◽  
Corticosteroid Binding Globulin ◽  
Globulin Gene

scholarly journals Post-COVID-19 Syndrome: The Persistent Symptoms at the Post-viral Stage of the Disease. A Systematic Review of the Current Data

2021 ◽  
Vol 8 ◽  
Author(s):  
Francesca Salamanna ◽  
Francesca Veronesi ◽  
Lucia Martini ◽  
Maria Paola Landini ◽  
Milena Fini
Keyword(s):  
Systematic Review ◽  
Chronic Fatigue ◽  
Current Data ◽  
Assessment Tools ◽  
Current Evidence ◽  
Case Control Studies ◽  
Cross Sectional ◽  
Persistent Symptoms ◽  
Collection Form

Whilst the entire world is battling the second wave of COVID-19, a substantial proportion of patients who have suffered from the condition in the past months are reporting symptoms that last for months after recovery, i. e., long-term COVID-19 symptoms. We aimed to assess the current evidence on the long-term symptoms in COVID-19 patients. We did a systematic review on PubMed, Web of Science, EMBASE, and Google Scholar from database inception to February 15, 2021, for studies on long-term COVID-19 symptoms. We included all type of papers that reported at least one long-term COVID-19 symptom. We screened studies using a standardized data collection form and pooled data from published studies. Cohort cross-sectional, case-report, cases-series, case-control studies, and review were graded using specific quality assessment tools. Of 11,361 publications found following our initial search we assessed 218 full-text articles, of which 145 met all selection criteria. We found that 20.70% of reports on long-term COVID-19 symptoms were on abnormal lung functions, 24.13% on neurologic complaints and olfactory dysfunctions, and 55.17% on specific widespread symptoms, mainly chronic fatigue, and pain. Despite the relatively high heterogeneity of the reviewed studies, our findings highlighted that a noteworthy proportion of patients who have suffered from SARS-CoV-2 infection present a “post-COVID syndrome.” The multifaceted understanding of all aspects of the COVID-19 pandemic, including these long-term symptoms, will allow us to respond to all the global health challenges, thus paving the way to a stronger public health.

scholarly journals Inhibition of Corticosteroid-Binding Globulin Gene Expression by Glucocorticoids Involves C/EBPβ

PLoS ONE ◽  
2014 ◽  
Vol 9 (10) ◽  
pp. e110702 ◽  
Author(s):  
Nicolette Verhoog ◽  
Fatima Allie-Reid ◽  
Wim Vanden Berghe ◽  
Carine Smith ◽  
Guy Haegeman ◽  
...  
Keyword(s):  
Gene Expression ◽  
Corticosteroid Binding Globulin ◽  
Globulin Gene

Corticosteroid Binding Globulin Gene Polymorphism Influences Cortisol Driven Fat Distribution in Obese Women

2005 ◽  
Vol 13 (9) ◽  
pp. 1485-1490 ◽  
Author(s):  
Pascal Barat ◽  
Martine Duclos ◽  
Blandine Gatta ◽  
Patrick Roger ◽  
Pierre Mormede ◽  
...  
Keyword(s):  
Gene Polymorphism ◽  
Fat Distribution ◽  
Obese Women ◽  
Corticosteroid Binding Globulin ◽  
Globulin Gene

Abstract 11621: Fibrillin-1 Gene Mutations in Left Ventricular Non-Compaction Cardiomyopathy

Circulation ◽  
2014 ◽  
Vol 130 (suppl_2) ◽  
Author(s):  
John J Parent ◽  
Jeffrey A Towbin ◽  
John L Jefferies
Keyword(s):  
Extracellular Matrix ◽  
Gene Mutation ◽  
Marfan Syndrome ◽  
Gene Mutations ◽  
Left Ventricular ◽  
Current Evidence ◽  
Causative Gene ◽  
Fbn1 Gene ◽  
Gene Testing ◽  
Fibrillin 1

Introduction: Left ventricular non-compaction cardiomyopathy (LVNC) is a rare and unique cardiomyopathy. Its presentation can range from a benign phenotype to overt heart failure and sudden cardiac death. The genetics of LVNC are not completely understood and current genetic testing has a yield of about 30% in identifying a causative gene mutation. We present a series of patients with LVNC and fibrillin-1 (FBN1) gene mutations. Hypothesis: We hypothesize that FBN1 gene mutations can lead to LVNC by way of its role in the myocardial extracellular matrix during cardiac development. Methods: A retrospective review of all patients with LVNC at our institution was performed for purposes of another investigation. The process unexpectedly identified patients with LVNC and FBN1 gene mutations, as well as LVNC and Marfan syndrome. Results: Approximately 150 patients are followed in our clinic with LVNC. We screened this population and found 51 patients on medical therapy for reduced function. We retrospectively reviewed gene testing in these 51 patients, when available, and identified 5 patients (10%) with an FBN1 gene mutation. All 5 patients had a dilated LVNC phenotype and previous or current evidence of left ventricular dysfunction. Syndrome breakdown as follows: 3 with Marfan, 1 with Shprintzen-Goldberg, and 1 with no identifiable syndrome. Dilated cardiomyopathy/LVNC gene testing was performed in 3 patients; 2 had disease causing myosin heavy chain 7 gene defects and 1 had no defects. Conclusions: The role of FBN1 in the human myocardium is not completely understood but it is expressed in the developing fetal heart and is a component of the myocardial extracellular matrix. Although causation has not been proven by our report, it certainly raises interest in a mechanistic relationship between LVNC and FBN1 given the increased prevalence of Marfan syndrome and probable increased prevalence of FBN1 gene mutations in this cohort of LVNC patients in light of FBN1.

scholarly journals Does the microbiome and virome contribute to myalgic encephalomyelitis/chronic fatigue syndrome?

2018 ◽  
Vol 132 (5) ◽  
pp. 523-542 ◽  
Author(s):  
Fiona Newberry ◽  
Shen-Yuan Hsieh ◽  
Tom Wileman ◽  
Simon R. Carding
Keyword(s):  
Chronic Fatigue Syndrome ◽  
Study Design ◽  
Chronic Fatigue ◽  
Myalgic Encephalomyelitis ◽  
Current Evidence ◽  
Fatigue Syndrome ◽  
Health And Disease ◽  
Host Lysis ◽  
Diagnosis Criteria ◽  
Endocrine Symptoms

Myalgic encephalomyelitis (ME)/chronic fatigue syndrome (CFS) (ME/CFS) is a disabling and debilitating disease of unknown aetiology. It is a heterogeneous disease characterized by various inflammatory, immune, viral, neurological and endocrine symptoms. Several microbiome studies have described alterations in the bacterial component of the microbiome (dysbiosis) consistent with a possible role in disease development. However, in focusing on the bacterial components of the microbiome, these studies have neglected the viral constituent known as the virome. Viruses, particularly those infecting bacteria (bacteriophages), have the potential to alter the function and structure of the microbiome via gene transfer and host lysis. Viral-induced microbiome changes can directly and indirectly influence host health and disease. The contribution of viruses towards disease pathogenesis is therefore an important area for research in ME/CFS. Recent advancements in sequencing technology and bioinformatics now allow more comprehensive and inclusive investigations of human microbiomes. However, as the number of microbiome studies increases, the need for greater consistency in study design and analysis also increases. Comparisons between different ME/CFS microbiome studies are difficult because of differences in patient selection and diagnosis criteria, sample processing, genome sequencing and downstream bioinformatics analysis. It is therefore important that microbiome studies adopt robust, reproducible and consistent study design to enable more reliable and valid comparisons and conclusions to be made between studies. This article provides a comprehensive review of the current evidence supporting microbiome alterations in ME/CFS patients. Additionally, the pitfalls and challenges associated with microbiome studies are discussed.

scholarly journals Krónikus orofacialis fájdalmak

2019 ◽  
Vol 160 (27) ◽  
pp. 1047-1056
Author(s):  
Gergely Fehér ◽  
Zsolt Nemeskéri ◽  
Gabriella Pusch ◽  
Iván Zádori ◽  
Gyula Bank ◽  
...  
Keyword(s):  
Neuropathic Pain ◽  
Healthcare Professionals ◽  
Orofacial Pain ◽  
Inflammatory Diseases ◽  
Current Evidence ◽  
Initial Management ◽  
Pain Syndromes ◽  
Chronic Orofacial Pain ◽  
The Common

Abstract: Orofacial pain is the common name of a variety of disorders from inflammatory diseases to neuropathic pain syndromes. This condition is quite common, it may involve 7% of the whole population. Patients (and doctors) are not aware of the origin of their complaints, therefore initial management falls among the variety of healthcare professionals. The aim of our review was to summarize the current evidence of chronic orofacial pain including diagnosis, management and pitfalls. Orv Hetil. 2019; 160(27): 1047–1056.

Sign in / Sign up

Export Citation Format

Share Document